Spelling suggestions: "subject:"combined oral contraceptive"" "subject:"combined oral contraception""
1 |
Avaliação hemodinâmica e da função endotelial em mulheres jovens normotensas em uso de anticoncepcional hormonal combinado oral contendo drospirenona / Assessment of hemodynamic and endothelial function in normotensive young women using a combined hormonal oral contraceptive containing drospirenoneGiribela, Cassiana Rosa Galvão 25 October 2011 (has links)
Importância. Anticoncepcionais hormonais combinados orais (AHCO) podem levar ao aumento do risco da doença cardiovascular, que pode estar associado a alterações na pressão arterial e na função endotelial. Objetivos. O objetivo deste estudo foi avaliar o impacto do uso de AHCO contendo 20 mg de etinilestradiol (EE) e 3 mg de drospirenona (DRSP) por mulheres jovens normotensas sobre a função endotelial arterial, pressão arterial sistólica (PAS, mmHg) e diástólica (PAD, mmHg), frequência cardíaca (FC, bpm), débito cardíaco (DC, L/min), e sobre a resistência periférica total (RPT, NU). Métodos. Setenta e uma mulheres jovens saudáveis com idade média de 29 ± 1 ano foram avaliadas. Quarenta e três foram analisadas antes da introdução do AHCO e ao final de 6 meses de uso (grupo-caso) e vinte e oito, não usuárias de nenhum método hormonal de contracepção, foram avaliadas quanto aos mesmos parâmetros no mesmo intervalo de tempo (grupo-controle). Resultados. Não se observaram mudanças significantes na função endotélio-dependente (VMF%) e independente (VIE%) e nas medidas de PAS, PAD, FC, DC e da RPT com o uso do AHCO (p> 0,05 para todas as variáveis). Não houve variações significantes nestes parâmetros no grupo-controle. Conclusão: O uso desta formulação de AHCO não causou alterações deletérias na reatividade vascular, e nas variáveis hemodinâmicas em mulheres jovens normotensas. / Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, possibly associated with changes in blood pressure and endothelial function. Objective: The objective was to evaluate the impact of COC containing 20 mcg of ethinyl estradiol (EE) and 3 mg of drospirenone (DRSP) on the arterial endothelial function, systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), cardiac output (CO), and total peripheral resistance (TPR) of normotensive young women. Methods: Of the 71 women in the study, 43 were evaluated before the introduction of COC and after 6 months of its use (case group) and 28, COC nonusers, were assessed for the same parameters at the same time interval (control group). Results: No significant changes in endothelium-dependent and -independent functions or in measures of SBP, DBP, HR, CO, and TPR caused by COC use were observed in the case group (P> 0.05 for all variables) or in the control group. Conclusion: These data suggest COC with 20 mcg EE and 3 mg DRSP does not alter arterial endothelial function or hemodynamic parameters in normotensive young women
|
2 |
Avaliação hemodinâmica e da função endotelial em mulheres jovens normotensas em uso de anticoncepcional hormonal combinado oral contendo drospirenona / Assessment of hemodynamic and endothelial function in normotensive young women using a combined hormonal oral contraceptive containing drospirenoneCassiana Rosa Galvão Giribela 25 October 2011 (has links)
Importância. Anticoncepcionais hormonais combinados orais (AHCO) podem levar ao aumento do risco da doença cardiovascular, que pode estar associado a alterações na pressão arterial e na função endotelial. Objetivos. O objetivo deste estudo foi avaliar o impacto do uso de AHCO contendo 20 mg de etinilestradiol (EE) e 3 mg de drospirenona (DRSP) por mulheres jovens normotensas sobre a função endotelial arterial, pressão arterial sistólica (PAS, mmHg) e diástólica (PAD, mmHg), frequência cardíaca (FC, bpm), débito cardíaco (DC, L/min), e sobre a resistência periférica total (RPT, NU). Métodos. Setenta e uma mulheres jovens saudáveis com idade média de 29 ± 1 ano foram avaliadas. Quarenta e três foram analisadas antes da introdução do AHCO e ao final de 6 meses de uso (grupo-caso) e vinte e oito, não usuárias de nenhum método hormonal de contracepção, foram avaliadas quanto aos mesmos parâmetros no mesmo intervalo de tempo (grupo-controle). Resultados. Não se observaram mudanças significantes na função endotélio-dependente (VMF%) e independente (VIE%) e nas medidas de PAS, PAD, FC, DC e da RPT com o uso do AHCO (p> 0,05 para todas as variáveis). Não houve variações significantes nestes parâmetros no grupo-controle. Conclusão: O uso desta formulação de AHCO não causou alterações deletérias na reatividade vascular, e nas variáveis hemodinâmicas em mulheres jovens normotensas. / Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, possibly associated with changes in blood pressure and endothelial function. Objective: The objective was to evaluate the impact of COC containing 20 mcg of ethinyl estradiol (EE) and 3 mg of drospirenone (DRSP) on the arterial endothelial function, systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), cardiac output (CO), and total peripheral resistance (TPR) of normotensive young women. Methods: Of the 71 women in the study, 43 were evaluated before the introduction of COC and after 6 months of its use (case group) and 28, COC nonusers, were assessed for the same parameters at the same time interval (control group). Results: No significant changes in endothelium-dependent and -independent functions or in measures of SBP, DBP, HR, CO, and TPR caused by COC use were observed in the case group (P> 0.05 for all variables) or in the control group. Conclusion: These data suggest COC with 20 mcg EE and 3 mg DRSP does not alter arterial endothelial function or hemodynamic parameters in normotensive young women
|
3 |
Prevention of Ovarian and Endometrial Cancer by Combined Oral Contraceptives: A Demographics StudyHeywood, Joanna S. 01 January 2017 (has links)
Endometrial cancer is the most common gynecologic cancer with 54,870 cases occurring in the United States in 2015 and causing 10,170 deaths, an 18.5% mortality rate (Elit and Reade, 2015). Ovarian cancer, while less common, is much more fatal. In 2015 in the United States, 21,290 cases occurred and resulted in 14,180 deaths, a 66.6% mortality rate. This mortality rate makes ovarian cancer the fifth most deadly cancer for women in the United States, which is largely explained by ineffective screening strategies and limited treatment possibilities (Cramer, 2012). Thus, developing effective prevention strategies is especially important to saving the lives of women who will develop ovarian or endometrial cancer. Women taking combined oral contraceptives (COCs), a type of hormonal birth control, have shown a significant reduced risk of developing ovarian and endometrial cancer. However, the Centers for Disease Control and Prevention (CDC) does not currently recommend taking COCs for the prevention gynecologic cancer (CDC, 2014a). Since the efficacy of COCs for reducing risk of ovarian and endometrial cancer is well established, guidelines need to be determined for populations of women that should take hormonal birth control to minimize cancer risk. This paper highlights the current understanding of ovarian and endometrial cancer, populations of women at highest risk for developing either of these two cancers, and then proposes a case-control study to help determine which populations of women should take hormonal birth control to reduce their gynecologic cancer risk.
|
4 |
Avaliação do efeito de contraceptivos hormonais sobre a hemostasia / Evaluation of the effect of hormonal contraceptives on hemostasis.Stocco, Bianca 26 September 2011 (has links)
RESUMO STOCCO, B. Avaliação do efeito de contraceptivos hormonais sobre a hemostasia. 2011. 92f. Dissertação (Mestrado). Faculdade de Ciências Farmacêuticas de Ribeirão Preto Universidade de São Paulo, Ribeirão Preto, 2011. Introdução: Mais de 100 milhões de mulheres no mundo fazem uso de métodos contraceptivos hormonais. Apesar de seu desejado efeito na contracepção, sua metabolização ocorre no fígado estimulando a síntese de proteínas plasmáticas, dentre elas, as que controlam os sistemas de coagulação e fibrinólise, conferindo um estado de hipercoagulabilidade em suas usuárias. A literatura aponta também alterações no metabolismo dos lipídios e carboidratos, além de modular a expressão de moléculas de adesão presentes no endotélio. Para combater os efeitos indesejáveis destes medicamentos, baixas concentrações de estrógenos e diferentes progestágenos foram introduzidos, pois, a estes últimos é conferida a atividade anti estrogênica destas formulações. Estudos independentes sugerem que progesteronas de terceira e quarta geração possuem atividade anti-estrogênica menor em relação as de segunda geração. Objetivos: avaliar a ocorrência de alterações hemostáticas, analisar o perfil lipídico e quantificar moléculas de adesão no soro ou plasma da população feminina brasileira usuária de contraceptivos orais de segunda e quarta gerações. Materiais e Métodos: 70 participantes distribuídas em quatro grupos a saber : grupo I (controle- 20 pacientes); grupo II (DRSP/30EE- 20 pacientes); grupo III (DRSP/20EE- 16 pacientes) e grupo IV (LNG/30EE-14 pacientes). Foram avaliados os seguintes parâmetros: TP, Fator VII, TTPA, Fator XII, Fibrinogênio, Fator 1+2, Proteína C, Proteína S, Antitrombina, D dímeros, PAI 1, VCAM, ICAM, E- selectina, HDL, LDL,VLDL, Colesterol total e Triglicérides. Resultados e discussões: grupo II promoveu diminuição em TP e Prot. S; e aumento em HDL,VLDL,Col. total e TG; grupo III diminuiu TP, TTPA, Prot.S, ICAM e VCAM ; e aumentou Fibrinogênio, D-dímeros, HDL,VLDL,Col. total e TG e grupo IV diminuiu TP, Prot.C e aumentou ICAM e VCAM. Conclusões: Dos medicamentos estudados apontamos que: o grupo II promoveu alterações significativas no perfil lipídico caracterizando um estado pró-trombótico, apesar de apresentar o maior aumento nos valores de HDL e poucas alterações associadas à hipercoagulabilidade; o grupo III promoveu o maior número de alterações hipercoagulantes, alterou também perfil lipídico contribuindo para um estado pró- trombótico, embora tenha apresentado proteção endotelial e o grupo IV foi o medicamento que promoveu melhor proteção endotelial, não alterou perfil lipídico e ocasionou poucas alterações associadas à hipercoagulabilidade / Introduction: More than 100 million women in the world make use of hormonal contraceptives. In spite of its desired effect on contraception, its metabolization occurs at liver, estimulating the synthesis of the plasmatic proteins, among them, the ones that control the coagulation system and fibrinolysis, confering a hypercoagulability state in their users. The literature also points changes in the metabolism of lipids and carbohydrates, besides modulate the expression of adhesion molecules present in the endothelium. Trying to combat undesirable effects of these drugs, low concentrations of estrogen and different progestogens were introduced, because, the antiestrogenic activity of these drugs is assigned to the progesterone used. Independent papers suggest that third and fourth generation progesterones have a smaller antiestrogenic activity in relation to the second generation one. Objectives: evaluate the occurrence of hemostatic alterations, analyze the lipid profile and quantify adhesion molecules in serum or plasma on the Brazilian female population who is user of contraceptives from second and fourth generation. Material and Methods: 70 participants were distributed into four groups: group I (control- 20 patients); group II (DRSP/30EE- 20 patients); group III (DRSP/20EE- 16 patients) and group IV (LNG/30EE- 14 patients). From these were assessed the following parameters: PT, Factor VII, APTT, Factor XII, Fibrinogen, Factor 1+2, Protein C, Protein S, Antithrombin, Ddimmers, PAI 1,VCAM, ICAM, E- selectin, HDL, LDL, VLDL, Total Cholesterol and Triglycerides.Results and discussion: group II promoted a decrease in PT and Prot.S; and an increase in HDL,VLDL, Total cholesterol and TG; group III decreased PT, APTT, Prot.S, ICAM and VCAM ; and increased Fribrinogen, D- dimers, HDL,VLDL,Total Cholesterol and TG and group IV decreased PT, Prot.C and increased ICAM and VCAM.Conclusions: among the drugs studied we aim that: the group II promoted significant changes in lipid profile featuring a pro- thrombotic state, in spite of presented the highest increase in the levels of HDL and few alterations associated to hypercoagulability; group III promoted the biggest number of hypercoagulability alterations, this drug also changed the lipid profile contributing to a pro-thrombotic state, although it has presented endothelial protection and the group IV it was the drug that promoted the best endothelial protection, did not change lipid profile and caused few alterations associated with hypercoagulability
|
5 |
Avaliação do efeito de contraceptivos hormonais sobre a hemostasia / Evaluation of the effect of hormonal contraceptives on hemostasis.Bianca Stocco 26 September 2011 (has links)
RESUMO STOCCO, B. Avaliação do efeito de contraceptivos hormonais sobre a hemostasia. 2011. 92f. Dissertação (Mestrado). Faculdade de Ciências Farmacêuticas de Ribeirão Preto Universidade de São Paulo, Ribeirão Preto, 2011. Introdução: Mais de 100 milhões de mulheres no mundo fazem uso de métodos contraceptivos hormonais. Apesar de seu desejado efeito na contracepção, sua metabolização ocorre no fígado estimulando a síntese de proteínas plasmáticas, dentre elas, as que controlam os sistemas de coagulação e fibrinólise, conferindo um estado de hipercoagulabilidade em suas usuárias. A literatura aponta também alterações no metabolismo dos lipídios e carboidratos, além de modular a expressão de moléculas de adesão presentes no endotélio. Para combater os efeitos indesejáveis destes medicamentos, baixas concentrações de estrógenos e diferentes progestágenos foram introduzidos, pois, a estes últimos é conferida a atividade anti estrogênica destas formulações. Estudos independentes sugerem que progesteronas de terceira e quarta geração possuem atividade anti-estrogênica menor em relação as de segunda geração. Objetivos: avaliar a ocorrência de alterações hemostáticas, analisar o perfil lipídico e quantificar moléculas de adesão no soro ou plasma da população feminina brasileira usuária de contraceptivos orais de segunda e quarta gerações. Materiais e Métodos: 70 participantes distribuídas em quatro grupos a saber : grupo I (controle- 20 pacientes); grupo II (DRSP/30EE- 20 pacientes); grupo III (DRSP/20EE- 16 pacientes) e grupo IV (LNG/30EE-14 pacientes). Foram avaliados os seguintes parâmetros: TP, Fator VII, TTPA, Fator XII, Fibrinogênio, Fator 1+2, Proteína C, Proteína S, Antitrombina, D dímeros, PAI 1, VCAM, ICAM, E- selectina, HDL, LDL,VLDL, Colesterol total e Triglicérides. Resultados e discussões: grupo II promoveu diminuição em TP e Prot. S; e aumento em HDL,VLDL,Col. total e TG; grupo III diminuiu TP, TTPA, Prot.S, ICAM e VCAM ; e aumentou Fibrinogênio, D-dímeros, HDL,VLDL,Col. total e TG e grupo IV diminuiu TP, Prot.C e aumentou ICAM e VCAM. Conclusões: Dos medicamentos estudados apontamos que: o grupo II promoveu alterações significativas no perfil lipídico caracterizando um estado pró-trombótico, apesar de apresentar o maior aumento nos valores de HDL e poucas alterações associadas à hipercoagulabilidade; o grupo III promoveu o maior número de alterações hipercoagulantes, alterou também perfil lipídico contribuindo para um estado pró- trombótico, embora tenha apresentado proteção endotelial e o grupo IV foi o medicamento que promoveu melhor proteção endotelial, não alterou perfil lipídico e ocasionou poucas alterações associadas à hipercoagulabilidade / Introduction: More than 100 million women in the world make use of hormonal contraceptives. In spite of its desired effect on contraception, its metabolization occurs at liver, estimulating the synthesis of the plasmatic proteins, among them, the ones that control the coagulation system and fibrinolysis, confering a hypercoagulability state in their users. The literature also points changes in the metabolism of lipids and carbohydrates, besides modulate the expression of adhesion molecules present in the endothelium. Trying to combat undesirable effects of these drugs, low concentrations of estrogen and different progestogens were introduced, because, the antiestrogenic activity of these drugs is assigned to the progesterone used. Independent papers suggest that third and fourth generation progesterones have a smaller antiestrogenic activity in relation to the second generation one. Objectives: evaluate the occurrence of hemostatic alterations, analyze the lipid profile and quantify adhesion molecules in serum or plasma on the Brazilian female population who is user of contraceptives from second and fourth generation. Material and Methods: 70 participants were distributed into four groups: group I (control- 20 patients); group II (DRSP/30EE- 20 patients); group III (DRSP/20EE- 16 patients) and group IV (LNG/30EE- 14 patients). From these were assessed the following parameters: PT, Factor VII, APTT, Factor XII, Fibrinogen, Factor 1+2, Protein C, Protein S, Antithrombin, Ddimmers, PAI 1,VCAM, ICAM, E- selectin, HDL, LDL, VLDL, Total Cholesterol and Triglycerides.Results and discussion: group II promoted a decrease in PT and Prot.S; and an increase in HDL,VLDL, Total cholesterol and TG; group III decreased PT, APTT, Prot.S, ICAM and VCAM ; and increased Fribrinogen, D- dimers, HDL,VLDL,Total Cholesterol and TG and group IV decreased PT, Prot.C and increased ICAM and VCAM.Conclusions: among the drugs studied we aim that: the group II promoted significant changes in lipid profile featuring a pro- thrombotic state, in spite of presented the highest increase in the levels of HDL and few alterations associated to hypercoagulability; group III promoted the biggest number of hypercoagulability alterations, this drug also changed the lipid profile contributing to a pro-thrombotic state, although it has presented endothelial protection and the group IV it was the drug that promoted the best endothelial protection, did not change lipid profile and caused few alterations associated with hypercoagulability
|
6 |
Ovarian Steroid Hormones, Emotion Processing and MoodGingnell, Malin January 2013 (has links)
It is known that some psychiatric disorders may deteriorate in relation to the menstrual cycle. However, in some conditions, such as premenstrual dysphoric disorder (PMDD), symptomatology is triggered mainly by the variations in ovarian steroid hormones. Although symptoms induced by fluctuations in ovarian steroids often are affective, little is known about how emotion processing in women is influenced by variations, or actual levels, of ovarian steroid hormones. The general aim of this thesis was to evaluate menstrual cycle effects on reactivity in emotion generating and controlling areas in the corticolimbic system to emotional stimulation and anticipation, in healthy controls and women with PMDD. A second aim was to evaluate corticolimbic reactivity during long-term administration of exogenous ovarian steroids. In study I, III and IV effects of the menstrual cycle on emotional reactivity in women with PMDD was studied. In study I, women with PMDD in displayed higher amygdala reactivity than healthy controls to emotional faces, not in the luteal phase as was hypothesised, but in the follicular phase. No difference between menstrual cycle phases was obtained in women with PMDD, while healthy controls had an increased reactivity in the luteal phase. The results of study I was further elaborated in study III, where women with PMDD were observed to have an increased anticipatory reactivity to negative emotional stimuli. However, no differences in amygdala reactivity to emotional stimuli were obtained across the menstrual cycle. Finally, in study IV the hypothesis that amygdala reactivity increase in the luteal phase in women with PMDD is linked to social stimuli rather than generally arousing stimuli was suggested, tested and supported. In study II, re-exposure to COC induced mood symptoms de novo in women with a previous history of COC-induced adverse mood. Women treated with COC reported increased levels of mood symptoms both as compared to before treatment, and as compared to the placebo group. There was a relatively strong correlation between depressive scores before and during treatment. The effects of repeated COC administration on subjective measures and brain function were however dissociated with increased aversive experiences accompanied by reduced reactivity in the insular cortex.
|
Page generated in 0.1073 seconds